Xperi Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Xperi Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.11M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $493.69M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $521.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $502.26M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $486.48M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $376.10M | Mar 6, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.11M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $493.69M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $521.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $502.26M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $486.48M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $376.10M | Mar 6, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($56.34M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($14.01M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($136.61M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($757.48M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($175.62M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | ($138.33M) | Mar 6, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($43.73M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($87.08M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($129.64M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($749.43M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($161.83M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | ($152.56M) | Mar 6, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $135.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $191.35M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $222.83M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $216.36M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $194.87M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $163.41M | Mar 6, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $181.87M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $218.11M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $233.40M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $217.40M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $199.92M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $172.59M | Mar 6, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($515.0K) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($55.34M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $62.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($28.45M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($23.45M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | ($23.78M) | Mar 6, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.38M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $6.82M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $13.10M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $8.89M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $6.60M | Mar 6, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $615.83M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $667.76M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $673.64M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $736.91M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.23B | Mar 6, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.75M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $238.68M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $286.50M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $287.93M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $212.76M | Mar 6, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $429.08M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $404.23M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $463.42M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.03B | Mar 6, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 6, 2023 |
| FY2022 | Dec 31, 2021 | $536.51M | Mar 6, 2023 |
| FY2022 | Dec 31, 2020 | $532.45M | Mar 6, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($895.78M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($839.44M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($805.45M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($668.84M) | Mar 1, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $96.82M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $130.56M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $142.09M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $160.13M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $120.70M | Mar 1, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.68M | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $27.68M | Feb 27, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (18) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Mar 6, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (18) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Mar 6, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.93M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 44.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 44.21M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 42.07M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 6, 2023 |